Tyra Biosciences Ownership
| TYRA Stock | USD 10.94 0.22 1.97% |
Tyra |
Tyra Stock Ownership Analysis
About 95.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.52. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tyra Biosciences has Price/Earnings To Growth (PEG) ratio of 0.28. The entity recorded a loss per share of 1.61. The firm had not issued any dividends in recent years. Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California. Tyra Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. To find out more about Tyra Biosciences contact the company at 619 728 4760 or learn more at https://tyra.bio.Tyra Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tyra Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tyra Biosciences backward and forwards among themselves. Tyra Biosciences' institutional investor refers to the entity that pools money to purchase Tyra Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Orbimed Advisors, Llc | 2024-12-31 | 1.5 M | Vanguard Group Inc | 2024-12-31 | 1.2 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 1 M | Vestal Point Capital Lp | 2024-12-31 | 990 K | 5am Venture Management, Llc | 2024-12-31 | 939.3 K | Kynam Capital Management, Lp | 2024-12-31 | 530.5 K | Geode Capital Management, Llc | 2024-12-31 | 517.6 K | State Street Corp | 2024-12-31 | 407.6 K | Pictet Asset Manangement Sa | 2024-12-31 | 354 K | Ra Capital Management, Llc | 2024-12-31 | 10.6 M | Boxer Capital Llc | 2024-09-30 | 6.4 M |
Tyra Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tyra Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tyra Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tyra Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tyra Biosciences Outstanding Bonds
Tyra Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tyra Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tyra bonds can be classified according to their maturity, which is the date when Tyra Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| TYSON FOODS INC Corp BondUS902494BH59 | View |
Tyra Biosciences Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 6th of March 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 31st of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tyra Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tyra Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tyra Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tyra Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tyra Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tyra Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tyra Biosciences is measured differently than its book value, which is the value of Tyra that is recorded on the company's balance sheet. Investors also form their own opinion of Tyra Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Tyra Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tyra Biosciences' market value can be influenced by many factors that don't directly affect Tyra Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tyra Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.